USANA Health Sciences (NYSE:USNA) Rating Reiterated by Pivotal Research

0
12

Pivotal Research reaffirmed their buy rating on shares of USANA Health Sciences (NYSE:USNA) in a report published on Wednesday, July 24th, AnalystRatings.com reports.

“We thought it noteworthy that the company projected average diluted shares outstanding of 22.7 million, given that 2Q diluted shares out were 23.4 million. To get to that average we expect the company will need to buy-in 1.9 million shares in the 2H. That will put average shares outstanding down 7.7% for the year. This is not so important for 2019, but it will be for next year when we see an earnings recovery of 27% at the net income line (still below 2018) but EPS growth of 38% owing to the reduced share count.”,” the firm’s analyst commented.

Several other brokerages have also commented on USNA. ValuEngine lowered shares of USANA Health Sciences from a hold rating to a sell rating in a research note on Wednesday, May 22nd. Tigress Financial started coverage on shares of USANA Health Sciences in a research note on Tuesday, April 16th. They set a buy rating on the stock. TheStreet lowered shares of USANA Health Sciences from a b- rating to a c+ rating in a research note on Thursday, July 11th. Finally, Sidoti lowered shares of USANA Health Sciences from a buy rating to a neutral rating and set a $70.00 price objective on the stock. in a research note on Wednesday, July 3rd. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $72.50.

Shares of NYSE:USNA opened at $67.06 on Wednesday. The stock’s fifty day moving average is $66.95. USANA Health Sciences has a 12 month low of $58.30 and a 12 month high of $134.65. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of 13.00 and a beta of 0.44.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported $0.91 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.93 by ($0.02). USANA Health Sciences had a return on equity of 27.22% and a net margin of 9.68%. The company had revenue of $256.00 million for the quarter, compared to analyst estimates of $254.66 million. During the same quarter in the prior year, the business earned $1.36 earnings per share. USANA Health Sciences’s revenue was down 15.1% compared to the same quarter last year. Analysts anticipate that USANA Health Sciences will post 3.9 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royce & Associates LP boosted its holdings in shares of USANA Health Sciences by 66.4% in the first quarter. Royce & Associates LP now owns 381 shares of the company’s stock valued at $32,000 after acquiring an additional 152 shares in the last quarter. LS Investment Advisors LLC purchased a new stake in shares of USANA Health Sciences in the second quarter valued at about $32,000. Advisory Services Network LLC purchased a new stake in shares of USANA Health Sciences in the second quarter valued at about $65,000. NEXT Financial Group Inc purchased a new stake in USANA Health Sciences during the second quarter worth about $79,000. Finally, Meeder Asset Management Inc. boosted its holdings in USANA Health Sciences by 737.6% during the second quarter. Meeder Asset Management Inc. now owns 1,558 shares of the company’s stock worth $123,000 after buying an additional 1,372 shares in the last quarter. Institutional investors own 59.12% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

See Also: What is the Russell 2000 Index?

Receive News & Ratings for USANA Health Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for USANA Health Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

LEAVE A REPLY

Please enter your comment!
Please enter your name here